Somatrem; Recombinant HGH

Specification

• Cat#: THP-0035
• Product Name: Somatrem; Recombinant HGH
• Description: The protein has the same amino acid sequence as human growth hormone except for an extra methionine at the end of the sequence chain to facilitate its manufacturing process. As endogenous growth hormone, it binds to dimeric growth hormone (GH) receptors located within the cell membranes of target tissue cells resulting in intracellular signal transduction and a host of pharmacodynamic effects.
• Sequences: Not Available
• Species: Human
• Molecular Weight: 22255.9518 Da
• Purity: >99% by SDS-Page and HPLC analysis
• Cas No: 82030-87-3
• Formula: C995H1537N263O301S8
• Endotoxin Level: <0.001 EU per 1 μg of the peptide by the LAL method
• Biological Activity: 3.3IU/mg

Pharmaceutical Information

• Pharmaceutical Application: Somatrem
• Applications: The product is a recombinant human growth hormone indicated for: (a) treatment of paediatric patients with growth failure due to growth hormone deficiency (GHD), (b) treatment of paediatric patients with growth failure due to idiopathic short stature (ISS), (c) treatment of paediatric patients with growth failure due to Turner syndrome (TS), (d) treatment of paediatric patients with growth failure due to chronic kidney disease (CKD) up to the time of renal transplantation, (e) treatment of adults with childhood-onset GHD, or (f) treatment of adults with adult-onset GHD.
• Examples of Clinical Use: Growth hormone deficiency (GHD), idiopathic short stature (ISS), Turner syndrome (TS) and chronic kidney disease (CKD)
• Pharmacodynamics: In vitro and in vivo preclinical and clinical testing have demonstrated that the product is therapeutically equivalent to pituitary derived human growth hormone (hGH). Paediatric patients who lack adequate endogenous growth hormone secretion, patients with chronic kidney disease, and patients with Turner syndrome that were treated with the product resulted in an increase in growth rate and an increase in insulin-like growth factor (IGF-1) levels similar to that seen with patients who possess endogenous pituitary derived hGH. With normalized levels of growth hormone and related mediator agents like IGF-1, patients demonstrate normalized skeletal, cell, organ, and overall tissue growth.
• Mechanism of action: Somatrem - as well as endogenous growth hormone - binds to dimeric growth hormone (GH) receptors located within the cell membranes of target tissue cells resulting in intracellular signal transduction and a host of pharmacodynamic effects. Some of these pharmacodynamic effects are primarily mediated by insulin like growth factor (IGF-1) produced in the liver and also locally (ie. skeletal growth, protein synthesis), while others are primarily a consequence of the direct effects of somatropin (ie. lipolysis).
• Affected organisms: Humans and other mammals
• Targets: Target 1. Growth hormone receptor; Target 2. Insulin-like growth factor 1 receptor